RLRenata Laškaj

Renata Laškaj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Renata Laškaj has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Longitudinal Changes in IgG N-glycome Are Associated with Disease Severity and Mortality in COVID-19 Patients

    by Martina Vinicki, Frano Vučković, Kristian Bodulić, Alemka Markotić, Zoran Barušić, Renata Laškaj, Ivan Christian Kurolt, Sanja Zember, Rok Čivljak, Ivan Puljiz, et al.

    Severe COVID-19 is characterized by immune dysregulation, yet reliable biomarkers associated with adverse outcomes remain limited. Immunoglobulin G (IgG) N-glycosylation modulates antibody effector function and reflects the immune system’s inflammatory state. In this study, we investigated whether specific IgG glycosylation profiles are associated with COVID-19 severity, mortality, and clinical course in patients without known prior SARS-CoV-2 infection. Of the 806 admitted COVID-19 patients included in the study, 377 hospitalized patients were longitudinally monitored, and 2001 serum samples were analyzed. Significant alterations in IgG N-glycome composition were observed in patients with severe disease and those who died. The most prominent changes included increased agalactosylation and decreased mono- and digalactosylation, features associated with a more pro-inflammatory IgG glycosylation profile. Nosocomial infections were associated with a more pro-inflammatory IgG glycosylation profile. No statistically significant differences in IgG N-glycome composition were observed between vaccinated and unvaccinated patients, although the small number of vaccinated patients limited this analysis. The observed glycomic profiles likely reflect immune responses characteristic of the early phase of the COVID-19 pandemic. Whether similar glycosylation changes occur in other infectious or inflammatory diseases remains to be established. IgG glycosylation analysis holds promise for personalized risk stratification and early therapeutic intervention in COVID-19 and other severe infectious diseases.


  • Open Access

    Prognostic Value of Biomarkers in COVID-19: Associations with Disease Severity, Viral Variants, and Comorbidities—A Retrospective Observational Single-Center Cohort Study

    by Zoran Barušić, Kristian Bodulić, Sanja Zember, Renata Laškaj, Rok Čivljak, Ivan Puljiz, Ivan-Christian Kurolt, Željka Mačak Šafranko, Lidija Cvetko Krajinović, Petra Svoboda Karić, et al.

    Coronavirus disease (COVID-19) exhibits a wide spectrum of clinical severity and has been associated with specific biomarkers linked to disease progression and outcomes. This retrospective study analyzed sera from 1222 adult COVID-19 patients hospitalized at the University Hospital for Infectious Diseases in Croatia. We examined the association between several laboratory biomarker levels measured at patient admission and disease severity, fatal outcomes, viral variants and clinical parameters. Deceased patients and surviving patients with severe COVID-19 exhibited significantly elevated levels of several biomarkers on admission, including hs-troponin T, N-terminal pro-brain natriuretic peptide, creatine kinase, C-reactive protein, procalcitonin, interleukin-6, lactate dehydrogenase, lactate, urea and creatinine. Random forest models identified lymphocyte percentage, D-dimers, and hs-troponin T as the most important biomarkers for fatal outcome prediction, achieving 84.1% accuracy. Patients infected with the Delta SARS-CoV-2 variant exhibited significantly higher levels of proinflammatory, cardiac and renal biomarkers. Vaccination correlated with reduced proinflammatory parameters and higher lymphocyte proportions. Hypertension, chronic renal disease and diabetes were associated with increased cardiac, renal and metabolic biomarker levels, respectively. These findings highlight the association of several laboratory biomarkers with COVID-19 severity, viral variants, vaccination status and comorbidities, potentially offering prognostic insights into COVID-19 outcomes.


  • Open Access

    Hemorrhagic Fever with Renal Syndrome Patients Exhibit Increased Levels of Lipocalin-2, Endothelin-1 and NT-proBNP

    by Lidija Cvetko Krajinović, Kristian Bodulić, Renata Laškaj, Branka Žibrat, Petra Svoboda Karić, Ivan-Christian Kurolt, Mihaela Kordun, Antea Topić, Rok Čivljak, Tomislava Skuhala, et al.

    Hemorrhagic fever with renal syndrome (HFRS) is an acute zoonotic disease caused by viruses of the Orthohantavirus genus. This syndrome is characterized by renal and cardiopulmonary implications detectable with different biomarkers. Here, we explored the role of serum and urine levels of lipocalin-2, endothelin-1 and N-terminal pro-brain natriuretic peptide (NT-proBNP) in HFRS pathology. A total of twenty-eight patients hospitalized due to a Puumala orthohantavirus infection were included, with serum and urine samples collected on patient admission (acute phase) and discharge (convalescent phase). In comparison to healthy individuals, patients exhibited significantly higher acute-phase serum and urine levels of lipocalin-2, serum levels of endothelin-1 and serum and urine levels of NT-proBNP. Patients in the convalescent phase showed a significant decrease in urine lipocalin-2, serum endothelin-1 and serum and urine NT-proBNP levels. We recorded a strong correlation between serum levels of lipocalin-2 and endothelin-1 and urine levels of lipocalin-2 with several kidney injury markers, such as serum creatinine, urea, urine white blood cell count and proteinuria. We also demonstrated an independent correlation of serum and urine lipocalin-2 levels with acute kidney injury in HFRS. All in all, our results show an involvement of NT-proBNP, lipocalin-2 and endothelin-1 in the renal and cardiac pathology of HFRS.